Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2000 Jul 17;10(14):1527-30.

Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.

Author information

1
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. thomas_rano@merck.com

Abstract

An efficient combination solution-phase/solid-phase route enabling the diversification of the P1', P2', and P3 subsites of indinavir has been established. The synthetic sequence can facilitate the rapid generation of HIV protease inhibitors possessing more favorable pharmacokinetic properties as well as enhanced potencies. Multiple compound dosing in vivo may also accelerate the identification of potential drug candidates.

PMID:
10915042
DOI:
10.1016/s0960-894x(00)00276-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center